KR20070122563A - 질병에의 면역학적 개입을 위한 1가 및 다가 합성 다당류항원 - Google Patents

질병에의 면역학적 개입을 위한 1가 및 다가 합성 다당류항원 Download PDF

Info

Publication number
KR20070122563A
KR20070122563A KR1020077026806A KR20077026806A KR20070122563A KR 20070122563 A KR20070122563 A KR 20070122563A KR 1020077026806 A KR1020077026806 A KR 1020077026806A KR 20077026806 A KR20077026806 A KR 20077026806A KR 20070122563 A KR20070122563 A KR 20070122563A
Authority
KR
South Korea
Prior art keywords
spa
epitope
epitopes
target
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077026806A
Other languages
English (en)
Korean (ko)
Inventor
래리 크리스 블라츠크자크
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20070122563A publication Critical patent/KR20070122563A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077026806A 2005-04-19 2006-04-19 질병에의 면역학적 개입을 위한 1가 및 다가 합성 다당류항원 Ceased KR20070122563A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67280705P 2005-04-19 2005-04-19
US60/672,807 2005-04-19

Publications (1)

Publication Number Publication Date
KR20070122563A true KR20070122563A (ko) 2007-12-31

Family

ID=37115904

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077026806A Ceased KR20070122563A (ko) 2005-04-19 2006-04-19 질병에의 면역학적 개입을 위한 1가 및 다가 합성 다당류항원

Country Status (8)

Country Link
US (1) US20090214598A1 (enExample)
EP (2) EP1874343A4 (enExample)
JP (1) JP2008539169A (enExample)
KR (1) KR20070122563A (enExample)
CN (1) CN101448517A (enExample)
AU (1) AU2006236294A1 (enExample)
CA (1) CA2605321A1 (enExample)
WO (1) WO2006113792A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067026A2 (en) 2006-09-29 2008-06-05 Michigan Technological University Purification of synthetic oligomers
WO2009059328A2 (en) * 2007-11-02 2009-05-07 The Johns Hopkins University Multi- component l2 vaccine for prevention of human papillomavirus infection
WO2010003178A1 (en) * 2008-07-07 2010-01-14 The University Of Melbourne A synthetic vaccine component
WO2012047639A2 (en) 2010-09-27 2012-04-12 Michigan Technological University Purification of synthetic oligonucleotides
ES2984980T3 (es) * 2015-04-17 2024-10-31 Symic Holdings Usa Inc Bioconjugados y usos de los mismos
SG11201911430PA (en) 2017-07-04 2020-01-30 Curevac Ag Novel nucleic acid molecules
EP3648774A4 (en) * 2017-07-07 2021-04-21 Symic IP, LLC SYNTHETIC BIOCONJUGATES
US12378328B2 (en) 2018-09-19 2025-08-05 Nanyang Technological University Biohybrid peptidoglycan oligomers
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
SU727647A1 (ru) 1977-11-02 1980-04-15 Институт биоорганической химии им.М.М.Шемякина Гликопептиды,обладающие противоопухолевой активностью и способ их получени
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5864008A (en) 1988-03-25 1999-01-26 James; Stephen Peptides derived from foot-and-mouth disease virus, pharmaceutical compositions, and methods for using the peptides
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US6423315B1 (en) 1993-03-03 2002-07-23 The University Of Tennessee Research Corp. Synthetic peptide for treatment of autoimmune arthritis
AUPM885194A0 (en) 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
JPH10509714A (ja) 1994-11-18 1998-09-22 ニューロクライン バイオサイエンシーズ， インコーポレイテッド ヒトミエリン塩基性タンパク質の９１位におけるペプチドアナログを用いる多発性硬化症の処置方法
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
WO1997005889A1 (en) * 1995-08-03 1997-02-20 Slesarev Vladimir I Non-specific vaccination by d-amino-acid containing compounds
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
IL120503A0 (en) 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
US6107021A (en) 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
JP4699612B2 (ja) 1999-02-05 2011-06-15 ザ ユニバーシティ オブ メルボーン Ｔヘルパー細胞エピトープ
FR2797202B1 (fr) 1999-08-02 2001-10-26 Genomic Equipement pour l'extraction automatique d'acides nucleiques
US20050235155A1 (en) 2001-08-03 2005-10-20 Porto Ranelli, Sa Identification of users on a network
US20030033351A1 (en) 2001-08-10 2003-02-13 Aleta Ricciardi Group proxy and method for grouping services in a distributed computing application
WO2003015815A1 (en) * 2001-08-21 2003-02-27 The Brigham And Women's Hospital, Inc. Improved conjugate vaccines
AU2003209623A1 (en) 2002-02-19 2003-09-09 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
CN1200590C (zh) 2002-03-01 2005-05-04 华为技术有限公司 一种实现gsm与cdma网络信令互通的方法
AU2003217685A1 (en) 2002-03-08 2003-09-22 Eli Lilly And Company Immunomodulatory polymeric antigens for treating inflammatory pathogies
EP2301972A1 (en) 2002-08-12 2011-03-30 The Council Of The Queensland Institute Of Medical Research Method to prepare immunogenic lipopeptides comprising T-helper and B-cell epitopes
US7833532B2 (en) 2002-08-12 2010-11-16 The Council Of The Queensland Institute Of Medical Research Immunogenic lipopeptides comprising T-helper and cytotoxic T lymphocyte (CTL) epitopes
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
AU2004229458B2 (en) 2003-04-11 2009-11-19 Antigenics, Inc. Improved heat shock protein-based vaccines and immunotherapies
CN100554279C (zh) 2003-09-17 2009-10-28 伊莱利利公司 用于疾病免疫干预的合成多糖抗原

Also Published As

Publication number Publication date
AU2006236294A1 (en) 2006-10-26
US20090214598A1 (en) 2009-08-27
CA2605321A1 (en) 2006-10-26
EP2407178A2 (en) 2012-01-18
WO2006113792A8 (en) 2007-01-11
EP1874343A2 (en) 2008-01-09
JP2008539169A (ja) 2008-11-13
WO2006113792A2 (en) 2006-10-26
EP1874343A4 (en) 2009-07-22
WO2006113792A3 (en) 2008-08-28
CN101448517A (zh) 2009-06-03

Similar Documents

Publication Publication Date Title
JP7179896B2 (ja) 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体
TWI379839B (en) Aβ immunogenic peptide carrier conjugates and methods of producing same
KR100598302B1 (ko) 백신 조성물
EP2547364B1 (en) Peptides, conjugates and method for increasing immunogenicity of a vaccine
TW200533681A (en) Immunogenic peptide carrier conjugates and methods of producing same
US7097837B2 (en) Synthetic vaccine agents
JPH09503742A (ja) ワクチン用免疫原性ｌｈｒｈペプチド構築体および合成普遍免疫刺激器
CN107522772B (zh) 短肽、其作为疫苗佐剂的应用及以所述短肽作为疫苗佐剂的疫苗
MX2007009598A (es) Moleculas inmunogenicas.
CN102711815B (zh) 用于疫苗的佐剂、包含所述佐剂的疫苗及其用途
FR2806727A1 (fr) Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
KR20070122563A (ko) 질병에의 면역학적 개입을 위한 1가 및 다가 합성 다당류항원
Schetters et al. Adaptable antigen matrix platforms for peptide vaccination strategies and T cell-mediated anti-tumor immunity
US20110142874A1 (en) Compositions, Methods, and Kits for Eliciting an Immune Response
EP2519263B1 (en) Lipopeptide- and lipoprotein-conjugates and its use
WO2019122050A1 (en) Methods of immunization
KR20220144830A (ko) 펩티드-멜라닌 결합 최적화
AU2809300A (en) Use of an enterobacterium protein OmpA associated with an antigen for generating an antiviral, antiparasitic or antitumoral cytotoxic response
CA2696068A1 (en) Compositions and methods for the treatment and prophylaxis of hypertension
CN117320743A (zh) 肽抗原载体蛋白
HK1130687A (en) Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
JP7513303B2 (ja) 腫瘍免疫増強剤、その調製方法および適用
WO2023106319A1 (ja) 抗ｉｌ－２３抗体誘導用ワクチン組成物
Zeng et al. Soluble Proteins Induce Strong CD8+ T Cell
FR2842812A1 (fr) Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071116

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110408

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130226

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130826

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130226

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I